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ABSTRACT  26 
Molecular markers for surveillance of Plasmodium falciparum resistance to current antimalarials are 27 
sorely needed. A 28-day efficacy study of artemether-lumefantrine in eastern Sudan identified 5 28 
treatment failures among 100 evaluable patients; nine further individuals were parasite positive by 29 
PCR during follow-up. Polymorphisms in pfatpase6 and pfmdr1 were evaluated by DNA sequencing. 30 
One individual carried parasites with a novel pfmdr1 polymorphism (F1044L). pfmdr1 gene 31 
amplification in parasites prior to treatment occurred in three individuals who had recurrent infection 32 
during follow-up.     33 
 34 
Abstract                     79 words   35 
 36 
37 
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Text                          1,509 words   38 
Artemisinin combination therapies (ACT) are strongly recommended for treating uncomplicated 39 
falciparum malaria (33). The most widely adopted of these combinations in sub-Saharan Africa is 40 
artemether-lumefantrine (AL) (32). The recent emergence of resistance to artemisinin on the Thai-41 
Cambodian border (23, 5) establishes an urgent need for validated molecular markers of resistance to 42 
ACT in general, and to AL in particular.  43 
 44 
Evidence from in vitro and in vivo studies has suggested that polymorphisms in the pfatpase6 locus, 45 
encoding P. falciparum SERCA (8, 16, 17, 28, 30), and in the pfmdr1 locus, encoding the parasite multi-46 
drug resistance transporter Pgh-1 (6, 7, 24, 25), may modulate plasmodium sensitivity to artemisinins 47 
(4, 12, 14, 26). Studies in Thailand show that copy number variation (CNV) of the pfmdr1 locus is 48 
associated with reduced in vivo and in vitro sensitivity to both mefloquine and AL (24, 25, 34). CNV 49 
has not been linked to treatment outcomes with AL in Africa (4, 14) although increased pfmdr1 copy 50 
number has been observed in isolates from Kenya and Gabon (13, 29), and confirmed in a few case 51 
studies of travellers returning from west Africa, mostly after mefloquine use (11, 35).   52 
 53 
In Sudan a 6-dose course of AL is currently recommended as second-line treatment for uncomplicated 54 
falciparum malaria (18), and has reported in vivo efficacy of over 90% (9, 20, 22). In the present study 55 
we analyse the sequence of pfatpase6 and pfmdr1 alleles, and test for CNV at pfmdr1, in parasites 56 
before and after AL treatment for uncomplicated falciparum malaria in eastern Sudan.    57 
 58 
Patients were recruited from among those presenting with fever or history of fever to clinics in the 59 
villages Asar, Daraweesh and Abu Adam near Gedaref town, and in a refugee camp in New-Halfa, an 60 
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irrigated area 150km from Gedaref. Inclusion criteria were a positive smear for P. falciparum mono-61 
infection, a parasite count of 1,000 – 100,000 asexual parasites/µl (Gedaref), or between 2,000 – 62 
200,000 asexual parasites/µl (New-Halfa), an axillary temperature ≥37.5°C, weight >10kg (Gedaref) or 63 
> 5kg (New-Halfa). Pregnant women, patients with other underlying disease or with signs of severe 64 
malaria (36) were excluded. Clinical assessment was performed on recruitment (D0) and days 1, 2, 3, 65 
7, 14, 21 and 28. Participants were treated with six doses of AL (20mg artemether/120mg 66 
lumefantrine tablets; Novartis). For adults, 4 tablets twice daily were administered; doses were 67 
adjusted according to weight for children under 35kg. The first dose each day was observed, the 68 
second dose was self-administered. Patients were advised to eat fatty food or milk before each dose. 69 
Giemsa-stained thick blood films were prepared and examined by microscopists on each day and a 70 
blood spot was collected onto glass fibre membranes for DNA analysis. 71 
 72 
DNA extraction utilised a modified Chelex® method (3). Amplification of both genes was attempted for 73 
all pre-treatment (D0) samples. Amplification of pfmdr1 fragment 1 (6) was attempted for all post-74 
treatment samples from day 14 and later. PCR-positive post-treatment samples were further analysed 75 
for other pfmdr1 regions and the pfatpase6 gene, using previously described methods for nested PCR 76 
methods and DNA sequencing (14, 19). Gene copy number was analysed by a duplex dual-labelled 77 
probe qPCR assay (24); two independent experiments were performed and in each experiment each 78 
isolate was tested in triplicate. Control DNA from P. falciparum lines 3D7 and HB3 (1 copy of pfmdr1 79 
each) and Dd2 (2 copies of pfmdr1) were run in parallel in each experiment. A sample was considered 80 
evaluable if it produced a duplex fluorescent signal in at least two replicates in each of the two 81 
experiments. Recrudescence was distinguished from re-infection by pfmsp-1 and pfmsp-2 genotyping 82 
(27).  83 











All participants received an information sheet in English and Arabic and provided signed written 85 
informed consent. Ethical approval was obtained from the Tropical Medicine Research Institute Ethics 86 
Review Committee, and the London School of Hygiene and Tropical Medicine Ethics Committee. The 87 
study was registered as a clinical trial (ID: NCT00440752). 88 
 89 
106 patients were recruited and 100 (94.3%) completed the follow-up. Mean age of recruits was 90 
similar in the two sites, being 16.7 years (95% C.I. 13.0 – 20.4) in Gedaref and 20.9 years (95% C.I. 15.8 91 
– 26.0) in New-Halfa (P = 0.19; 2-tailed Student’s t-test). By per protocol analysis, 95 patients (95%) 92 
displayed adequate clinical and parasitological response, with 5 individuals failing treatment. The PCR-93 
corrected estimate of therapeutic efficacy was 98%, as three recurrent infections displayed different 94 
msp-1 and msp-2 genotypes from the original infection. Eleven individuals were positive by pfmdr1 95 
PCR on day 14; three of these remained positive and a further one and two individuals became 96 
positive on day 21 and 28 respectively, making a total of 14 recurrent infections identified by PCR; all 97 
five individuals identified as treatment failures by microscopy were PCR positive.      98 
 99 
Codons 225 - 423 and 470 – 906 of the pfatpase6 gene (52% of the locus) were successfully 100 
sequenced in 78 and 87 pre-treatment isolates, respectively. 569K occurred in 49.4% of isolates. The 101 
synonymous polymorphism nt2694 T-A was detected in 59.3% of these isolates. A novel non-102 
synonymous change (D845N) was detected in 2 isolates. Other previously reported polymorphisms 103 
were also observed (Table 1). Three D14, one D21 and two D28 isolates were successfully sequenced, 104 
and pfatpase6 alleles were compared with those present in the same individual prior to treatment 105 
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(Table 2). Considerable diversity in this locus is confirmed in this seasonal low transmission setting, 106 
but the six evaluable recurrent infections were not associated with particular pfatpase genotypes.  107 
 108 
A novel polymorphism, F1044L, was observed in pfmdr1 in a single multi-clonal pre-treatment isolate; 109 
parasites with wild-type sequence at this codon were also present. All isolates, pre- and post-110 
treatment, carried the wild-type amino acids Ser and Asn at codons 1034 and 1042, respectively, in 111 
pfmdr1. Haplotypes of pfmdr1 were constructed at codons 86, 184 and 1246 for all isolates with 112 
complete data; four isolates with unambiguous mixtures of two haplotypes were each counted as 113 
harbouring both. The haplotype YFD was the most common prior to treatment, occurring in 67.4% of 114 
the 89 evaluable samples with unambiguous haplotypes, followed by YYD (15.7%), NYD (7.9%), NFD 115 
(5.6%), YYY ( 4.5%), YFY ( 2.2%) and NFY (1.1%). In contrast, NFD was relatively more abundant in 116 
post-treatment isolates (Table 3), being found alone or mixed in five of the fourteen post-treatment 117 
isolates (odds ratio 9.33; 95% C.I. 1.72 - 48.2; Fisher’s exact P = 0.004). 118 
 119 
Seventy-four pre-treatment and 14 post-treatment isolates were investigated for evidence of pfmdr1 120 
amplification. Copy number estimates of 1.03, 0.81 and 2.19 were obtained for 3D7, HB3 and Dd2. 121 
Reliable estimates of pfmdr1 copy number from at least two independent experiments were obtained 122 
for 57 pre-treatment and 2 post-treatment isolates. The average copy number in pre-treatment 123 
isolates was 1.24 (range 0.73 – 2.33; 95% CI; 1.16 – 1.32); pfmdr1 copy number estimates above 1.8 in 124 
at least two independent experiments were obtained for three pre-treatment isolates (Figure 1). Each 125 
of these individuals also had recurrent parasitaemia during follow-up; one case was microscopy 126 
positive on day 14 and typed by pfmsp2 genotyping as a recrudescence, whereas the remaining two 127 
cases were classified as ACPR but positive by PCR on day 14. There was thus an association between 128 
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carriage of parasites with amplified pfmdr1 copy number, prior to treatment, and recurrent 129 
parasitaemia after AL (Fisher’s exact test, P = 0.011). Two post-treatment isolates were successfully 130 
tested and both of these carried one copy of the pfmdr1 gene.  Interestingly, pfmdr1 amplified 131 
isolates in this study carried the 86Y allele instead of the N86 seen in South East Asia (Table 3). This 132 
observation is consistent with other African reports (13, 29; Maja Malmberg, Malaria Research Lab, 133 
Department of Medicine, Karolinska Institutet, Stockholm, Sweden; pers. comm.).  134 
 135 
The NFD allele is suggested to appear in re-infecting rather than recrudescing parasites following AL 136 
treatment (4, 12, 14, 26). Consistent with this view, two of the clinical failures in this study were 137 
classified as new infections by msp-1/2 genotyping. These were late failures from New-Halfa where 138 
the irrigation canals provide a stable mosquito habitat. In contrast, some earlier cases of parasite 139 
recurrence were identified by PCR in Gedaref where the possibility of re-infection is low. The 140 
observation of a new substitution at codon Phe1044Leu, and the amplification of pfmdr1, suggests 141 
diversification of this locus may be occurring. However, as the number of observations in our study 142 
was small, these preliminary findings need to be confirmed in larger studies.  143 
  144 
AL proved efficacious for treating uncomplicated malaria caused by P. falciparum in this study across 145 
two sites in eastern Sudan. We identified sub-patent parasitaemia in 10 patients with ACPR, but 146 
cannot rule out that gametocytes of P. falciparum were the origin of this DNA in at least some of 147 
these individuals. Selection by AL for genotypes at the pfatpase6 locus was not observed, but 148 
evidence was found of selection by AL for the pfmdr1 haplotype NFD in recurrent parasitaemia as 149 
early as D14 after treatment. We present the first evidence from an African efficacy study that 150 
amplification of the pfmdr1 locus may contribute to recurrent P. falciparum parasitaemia following AL 151 
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therapy. This association needs to be confirmed in larger studies, particularly as we lack locus 152 
amplification data for post-treatment isolates. There is published evidence that injectable artemether 153 
mono-therapy has been in use by medical practitioners in northern Sudan (1, 10, 21), and this may 154 
have led to selection of parasites carrying this gene amplification (15, 31); no such amplification was 155 
observed among 24 isolates collected in 1989 (2). Continual surveillance of pfmdr1 and other loci 156 
implicated in antimalarial treatment response is justified as large-scale use of ACT continues in sub-157 
Saharan Africa.  158 
 159 
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37. Table 1.  Diversity of pfatpase6 at recruitment. 268 
Study site 
L402V N569K G639D E643Q I723V I735M D845N 
L V N K G D E Q I V I M D N 
New Halfa 35 4 22 20 41 1 41 1 42 0 39 3 40 2 
Gedaref 35 4 22 23 44 1 45 0 42 3 42 1 39 0 
Total 70 8 44 43 85 2 86 1 84 3 81 4 79 2 
Amplification primers   269 
nest 1: ATP6_FOR1 5’-AATAAAACTCCCGCTGATGC-3; ATP6_REV1 5’-ATCCTTCTTCTCCATCATCC-3’ 270 
nest 2: ATP6_FOR1; ATP6_REV2 5’-CGTTAAAGCTTCAACATTTCC-3’ (800bp). 271 
Changed amino acid in bold; L; leucine, V; valine, N; asparagine, K; lysine, G; glycine, D; aspartic acid, E; glutamic acid, Q; glutamine, I; 272 
isoleucine, M;methionine.  273 
The E431K polymorphism was not investigated in this study. 274 
 275 
 276 
Table 2.  Comparison of pfatpase-6 in pre-treatment and post-treatment isolates 277 
Sample Day-0 Day-14 Day-21 Day-28 Treatment out come 
9 LKGEIIDA  -NGEIIDA**  LPF  Day-21 
19 LNGEIIDA   -NGEIMDT LCF Day-28 
56 * -KGEIIDT -KGEIIDT/A**   ACPR 
59 -NGEIIDT LNGEIIDT   LPF Day-14 
74 * VKGEIIDT -KGEIIDT  -KGEIIDA ACPR 
 278 
Amino acids L402V, N569K, G639D, E643Q, I723V, I735M, D845N & nucleotide T2694A 279 
Changed amino acid in bold, T; threonine, A; alanine. 280 
ACPR: adequate clinical and parasitological response; LPF: late parasitological failure; LCF: late clinical failure 281 
*PCR positive on follow up, not a clinical failure  282 
**Mixed at position T2964A 283 
- DNA not available284 












Table 3. Longitudinal analysis of pfmdr1 haplotypes in 14 patients with recurrent parasitaemia  287 
Site Patient ID 
Day 0 
haplotype 









9 YFD wt  NFD* LPF 
19 YYD wt  NFD LCF 
Gedaref 
56 YFD wt NYD  ACPR 
59 YFD 2 copies NFD  LPF 
61 YFD wt YFD  ACPR 
62 YFD wt NFD  LPF 
63 YFY 2 copies NFD  ACPR 
64 NYD wt NYY  LCF 
65 YFD wt NYD  ACPR 
68 YYD wt YFD  ACPR 
73 YFD wt YFD  ACPR 
74 YFD wt  YFD ACPR 
75 YFD 2 copies NYD  ACPR 
82 YFD -  NYD ACPR 
*Day 21 288 
Individuals shown include those with sub-microscopic PCR-positive parasitaemia. 289 
Wt: wild-type with respect to pfmdr1 CNV.  290 















FIGURE LEGENDS 296 
 297 
Figure 1.  Frequency distribution of pfmdr1 copy number estimates.  298 
Estimates of pfmdr1 locus copy numbers obtained from 55 pre-treatment isolates with complete 299 
follow-up data are grouped in bins of 0.1 copy units. The values shown represent the mean of at 300 
least two independent experiments; each DNA sample in each experiment was run in duplicate. Red 301 
data are pre-treatment parasite isolates from patients without subsequent recurrent parasitaemia. 302 
Green data are pre-treatment parasite isolates from patients with later recurrent parasitaemia by 303 
microscopy and/or PCR.  Isolates with copy number estimates of 1.8 and above were considered 304 
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